Celyad Oncology SA (CYAD) Reports Q2 Loss of $1.02

Celyad Oncology SA (NASDAQ: CYAD) reported Q2 EPS of ($1.02), versus ($1.19) reported last year.

"We continue to blaze a path forward by developing new technologies to advance allogeneic CAR T therapies, including our proprietary shRNA platform for allogeneic CAR T production and ‘armored’ CAR capabilities with co-expression of secreting cytokines, starting with IL-18. The innovations we are making through our clinical development pipeline and new technologies were the focus of our R&D day last month. This is an exciting time in our Company’s history as we plan for a steady stream of milestones in the second half of 2021,” commented Filippo Petti, Chief Executive Officer of Celyad Oncology. “We plan on announcing multiple clinical updates in the next six months that are expected to help further the progress of our lead programs and proprietary shRNA platform for the development of next-generation allogeneic CAR Ts.”

For earnings history and earnings-related data on Celyad Oncology SA (CYAD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
• Home Depot beats estimates, reaffirms fiscal 2026 guidance